Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel.

ABSTRACT:

Unlabelled

Background

Current protocols for the treatment of ovarian cancer include combination chemotherapy with a platinating agent and a taxane. However, many patients experience relapse of their cancer and the development of drug resistance is not uncommon, making successful second line therapy difficult to achieve. The objective of this study was to develop and characterize a cell line resistant to both carboplatin and docetaxel (dual drug resistant ovarian cell line) and to compare this cell line to cells resistant to either carboplatin or docetaxel.

Methods

The A2780 epithelial endometrioid ovarian cancer cell line was used to select for isogenic carboplatin, docetaxel and dual drug resistant cell lines. A selection method of gradually increasing drug doses wa

SUBMITTER: Armstrong SR 

PROVIDER: S-EPMC3541348 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature